Huntsworth has purchased 85% of Kyne for £13.7m. Kyne provides PR and patient advocacy services to a variety biotech and pharmaceutical clients. The company’s founder, David Kyne, will continue in his role, and the company will sit within Huntworth’s marketing division.
Huntsworth has also purchased 70% of CC, a strategic market access, health economics and outcomes research consultancy in Luxembourg, for £13.6m. CC’s founder Professor Mondher Toumi will continue in his role, and the company will sit within Huntsworth’s medical division.
“Huntsworth makes two strategic acquisitions. “
Paul Taaffe, CEO of Huntsworth, said: "CC brings health economics and market access to enhance the scientific evidence capability of MEDiSTRAVA, our medical division. KYNE brings an expanded capability in healthcare public relations and patient advocacy to the Evoke Group to support additional briefs from global clients. These acquisitions demonstrate Huntsworth’s commitment to supporting the changing needs of pharmaceutical and biotech clients."